NCT05081921 - Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases | Biotech Hunter

Enrollment

192

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

February 20, 2024

Study Completion Date

February 20, 2024

Conditions

Osteoarthritis of Knee

Interventions

DRUG

MesoCellA-Ortho administration

"Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups."

DRUG

HA administration

"Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups."

Trial Locations (1)

43-150

Galen - Ortopedia Sp. Z O.O., Bieruń